PURPOSE: This study aimed to evaluate whether cancers in the upper third of the rectum should be treated according to colon or rectal cancer guidelines. METHODS: We evaluated 499 patients with tumors located in the sigmoid colon (299 patients, 60%), the upper third of the rectum (95 patients, 19%), or the middle third of the rectum (105 patients, 21%), International Union against Cancer tumor stage II or III, no preoperative radiochemotherapy, and primary curative tumor resection between 1990 and 2006. Patients' surgical, histopathological, and prognostic parameters were compared. The median follow-up time was 80 months. RESULTS: Patients with sigmoid cancer showed a trend of significantly better estimated cause-specific survival (5-y value +/- 95% CI: 83.6 +/- 4.7%) compared with patients with rectal cancers of the upper third of the rectum (5-y value +/- 95% CI: 74.3 +/- 9.6%) or the middle third of the rectum (5-y value +/- 95% CI: 73.4 +/- 9.2%) (P = .063). Tumor location was an independent prognostic parameter (P = .036), with an increased risk of cause-specific death for rectal cancers of the upper third (hazard ratio, 1.87; P = .007) and of the middle third (hazard ratio, 1.43; P = .022) compared with sigmoid cancers. Stratification of upper third rectal cancers according to tumor grade, tumor infiltration depth (pT), and lymph node status (pN) identified a high-risk group. CONCLUSIONS: Cancers of the upper third of the rectum have more similarities with rectal cancers of the middle third of the rectum than with sigmoid cancers. A subgroup of patients with upper third rectal cancer can be identified who may require a more aggressive therapy than only primary resection followed by adjuvant therapy.
PURPOSE: This study aimed to evaluate whether cancers in the upper third of the rectum should be treated according to colon or rectal cancer guidelines. METHODS: We evaluated 499 patients with tumors located in the sigmoid colon (299 patients, 60%), the upper third of the rectum (95 patients, 19%), or the middle third of the rectum (105 patients, 21%), International Union against Cancer tumor stage II or III, no preoperative radiochemotherapy, and primary curative tumor resection between 1990 and 2006. Patients' surgical, histopathological, and prognostic parameters were compared. The median follow-up time was 80 months. RESULTS:Patients with sigmoid cancer showed a trend of significantly better estimated cause-specific survival (5-y value +/- 95% CI: 83.6 +/- 4.7%) compared with patients with rectal cancers of the upper third of the rectum (5-y value +/- 95% CI: 74.3 +/- 9.6%) or the middle third of the rectum (5-y value +/- 95% CI: 73.4 +/- 9.2%) (P = .063). Tumor location was an independent prognostic parameter (P = .036), with an increased risk of cause-specific death for rectal cancers of the upper third (hazard ratio, 1.87; P = .007) and of the middle third (hazard ratio, 1.43; P = .022) compared with sigmoid cancers. Stratification of upper third rectal cancers according to tumor grade, tumor infiltration depth (pT), and lymph node status (pN) identified a high-risk group. CONCLUSIONS:Cancers of the upper third of the rectum have more similarities with rectal cancers of the middle third of the rectum than with sigmoid cancers. A subgroup of patients with upper third rectal cancer can be identified who may require a more aggressive therapy than only primary resection followed by adjuvant therapy.
Authors: Olga A Lavryk; Elena Manilich; Michael A Valente; Arshiya Miriam; Emre Gorgun; Matthew F Kalady; Sherief Shawki; Conor P Delaney; Scott R Steele Journal: Int J Colorectal Dis Date: 2019-11-27 Impact factor: 2.571
Authors: Fred K Tabung; Susan E Steck; Yunsheng Ma; Angela D Liese; Jiajia Zhang; Bette Caan; Lifang Hou; Karen C Johnson; Yasmin Mossavar-Rahmani; Nitin Shivappa; Jean Wactawski-Wende; Judith K Ockene; James R Hebert Journal: Cancer Causes Control Date: 2014-12-31 Impact factor: 2.506
Authors: Leonardo C Duraes; Scott R Steele; Michael A Valente; Olga A Lavryk; Tara M Connelly; Hermann Kessler Journal: Int J Colorectal Dis Date: 2022-03-21 Impact factor: 2.571
Authors: A A J Grüter; A S van Lieshout; S E van Oostendorp; J C F Ket; M Tenhagen; F C den Boer; R Hompes; P J Tanis; J B Tuynman Journal: Tech Coloproctol Date: 2022-08-29 Impact factor: 3.699
Authors: S A Käser; J Froelicher; Q Li; S Müller; U Metzger; M Castiglione; U T Laffer; C A Maurer Journal: Langenbecks Arch Surg Date: 2014-08-28 Impact factor: 3.445
Authors: K Søndenaa; P Quirke; W Hohenberger; K Sugihara; H Kobayashi; H Kessler; G Brown; V Tudyka; A D'Hoore; R H Kennedy; N P West; S H Kim; R Heald; K E Storli; A Nesbakken; B Moran Journal: Int J Colorectal Dis Date: 2014-01-31 Impact factor: 2.571
Authors: Eun Joo Jung; Chun Geun Ryu; Gangmi Kim; Su Ran Kim; Sang Eun Nam; Hee Sun Park; Young Jun Kim; Dae-Yong Hwang Journal: Radiol Oncol Date: 2012-11-09 Impact factor: 2.991